End-of-day quote
Taipei Exchange
18:00:00 2024-05-20 EDT
|
5-day change
|
1st Jan Change
|
44.7
TWD
|
-1.00%
|
|
-1.97%
|
+16.41%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,055
|
2,921
|
4,977
|
3,654
|
2,923
|
1,350
|
Enterprise Value (EV)
1 |
1,576
|
2,599
|
4,660
|
3,219
|
2,718
|
1,081
|
P/E ratio
|
-6.36
x
|
-6.61
x
|
-12.2
x
|
-7.87
x
|
-15.5
x
|
-32.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
267
x
|
225
x
|
373
x
|
527
x
|
184
x
|
66.9
x
|
EV / Revenue
|
204
x
|
200
x
|
349
x
|
464
x
|
171
x
|
53.5
x
|
EV / EBITDA
|
-6.15
x
|
-6.31
x
|
-12
x
|
-7.08
x
|
-14.4
x
|
-29.2
x
|
EV / FCF
|
-9.16
x
|
-9.41
x
|
-22.8
x
|
-52.9
x
|
-19
x
|
-14.6
x
|
FCF Yield
|
-10.9%
|
-10.6%
|
-4.39%
|
-1.89%
|
-5.27%
|
-6.84%
|
Price to Book
|
2.91
x
|
4.77
x
|
8.88
x
|
8.25
x
|
11.7
x
|
3.78
x
|
Nbr of stocks (in thousands)
|
22,273
|
26,013
|
28,474
|
30,745
|
30,745
|
35,165
|
Reference price
2 |
92.27
|
112.3
|
174.8
|
118.8
|
95.07
|
38.40
|
Announcement Date
|
19-03-14
|
20-03-06
|
21-03-26
|
22-03-18
|
23-03-06
|
24-03-19
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7.706
|
12.97
|
13.34
|
6.939
|
15.86
|
20.2
|
EBITDA
1 |
-256.2
|
-412.1
|
-388.7
|
-454.5
|
-189.1
|
-36.99
|
EBIT
1 |
-301
|
-416.6
|
-395.6
|
-458.6
|
-191.5
|
-45.5
|
Operating Margin
|
-3,906.36%
|
-3,212.67%
|
-2,966.74%
|
-6,609.3%
|
-1,207.5%
|
-225.3%
|
Earnings before Tax (EBT)
1 |
-294.1
|
-408.6
|
-398.9
|
-458.6
|
-188.7
|
-38.17
|
Net income
1 |
-294.1
|
-408.6
|
-398.9
|
-458.6
|
-188.7
|
-38.17
|
Net margin
|
-3,816.86%
|
-3,151.36%
|
-2,991.29%
|
-6,608.98%
|
-1,189.8%
|
-189.01%
|
EPS
2 |
-14.51
|
-16.98
|
-14.34
|
-15.10
|
-6.137
|
-1.191
|
Free Cash Flow
1 |
-172.1
|
-276.2
|
-204.6
|
-60.81
|
-143.2
|
-73.89
|
FCF margin
|
-2,232.7%
|
-2,130.01%
|
-1,534.13%
|
-876.33%
|
-903.05%
|
-365.84%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-03-14
|
20-03-06
|
21-03-26
|
22-03-18
|
23-03-06
|
24-03-19
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
479
|
322
|
317
|
434
|
205
|
269
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-172
|
-276
|
-205
|
-60.8
|
-143
|
-73.9
|
ROE (net income / shareholders' equity)
|
-41.2%
|
-62%
|
-68%
|
-91.4%
|
-54.5%
|
-12.6%
|
ROA (Net income/ Total Assets)
|
-22.8%
|
-33.2%
|
-29.5%
|
-33%
|
-19%
|
-6.98%
|
Assets
1 |
1,290
|
1,231
|
1,353
|
1,391
|
994.1
|
547
|
Book Value Per Share
2 |
31.70
|
23.50
|
19.70
|
14.40
|
8.100
|
10.20
|
Cash Flow per Share
2 |
21.20
|
14.90
|
18.90
|
18.00
|
8.750
|
7.530
|
Capex
1 |
2.99
|
3.55
|
5.12
|
0.29
|
0.14
|
0.42
|
Capex / Sales
|
38.84%
|
27.38%
|
38.42%
|
4.15%
|
0.85%
|
2.05%
|
Announcement Date
|
19-03-14
|
20-03-06
|
21-03-26
|
22-03-18
|
23-03-06
|
24-03-19
|
|
1st Jan change
|
Capi.
|
---|
| +16.41% | 48.64M | | +8.63% | 114B | | +13.17% | 107B | | -12.76% | 22.22B | | -3.06% | 21.28B | | -7.19% | 17.51B | | -39.93% | 17.17B | | +6.67% | 14.14B | | +33.90% | 12.2B | | -28.60% | 7.83B |
Bio Therapeutic Drugs
|